Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Wegovy and Mounjaro/Zepbound are the two most effective approved weight loss medications available. Wegovy is semaglutide 2.4 mg weekly. Mounjaro is tirzepatide up to 15 mg weekly, approved for diabetes; Zepbound is the same drug in the obesity indication. On average weight loss, tirzepatide at maximum dose outperforms semaglutide at maximum dose — but both are transformational compared to all previous obesity medications.
The Efficacy Numbers
Wegovy (semaglutide 2.4 mg) — STEP 1 trial: 14.9% average body weight loss over 68 weeks. 32% of participants lost 20% or more of body weight.
Zepbound (tirzepatide 15 mg) — SURMOUNT-1 trial: 20.9% average body weight loss over 72 weeks. 56% of participants lost 20% or more of body weight.
These figures reflect the general (non-diabetes) obesity population in placebo-controlled trials. The difference is clinically meaningful — 6 percentage points of body weight. For a 90 kg person, the difference is approximately 5.4 kg additional weight loss on tirzepatide.
Why the Difference Exists
Wegovy (semaglutide) activates GLP-1 receptors only. Mounjaro/Zepbound (tirzepatide) activates both GLP-1 and GIP receptors simultaneously. The GIP addition enhances weight loss through additive and synergistic mechanisms that include direct fat cell effects and amplified hypothalamic appetite suppression.
The Missing Head-to-Head Trial
As of mid-2025, no published randomised controlled trial has directly compared semaglutide 2.4 mg (Wegovy) to tirzepatide 15 mg (Zepbound) in a non-diabetic obesity population. The SURPASS-2 trial compared them in type 2 diabetes at lower doses (semaglutide 1 mg vs tirzepatide 5, 10, 15 mg), showing tirzepatide winning at all doses.
The indirect comparison from separate trials (STEP 1 vs SURMOUNT-1) is the current basis for the efficacy claim. Both trials were rigorous, used similar populations, and produced consistent results with the same weight loss advantage for tirzepatide.
Cardiovascular Evidence
Semaglutide has a significant advantage in cardiovascular evidence. The SELECT trial (2023) showed Wegovy reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with overweight or obesity and established cardiovascular disease — a major outcome milestone.
A comparable cardiovascular outcome trial for tirzepatide (SURPASS-CVOT) has not yet reported results. Tirzepatide is expected to show cardiovascular benefit based on mechanism and early data, but it does not yet have the same level of evidence as Wegovy in this respect.
Cost and Availability
Both Wegovy and Zepbound carry high list prices in markets without insurance coverage. In some markets, Wegovy is more widely available due to its longer market presence. Zepbound received FDA approval more recently (late 2023) and is still expanding internationally.
In Pakistan, neither is officially DRAP-registered. Access through informal import channels carries the same authenticity and cold chain risks for both.
Side Effects
Both are well-tolerated at maximum doses by the majority of patients with active dose management. Wegovy has a slightly higher reported nausea rate at maximum dose than Zepbound. Both produce the same class of GI side effects and share the same contraindications (MTC/MEN2 history, pancreatitis history caution).
The METASLIM Alternative
For Pakistani patients for whom both Wegovy and Mounjaro/Zepbound are inaccessible through official channels, METASLIM provides physician-guided GLP-1 pathway support — the receptor target both drugs share — through DRAP-registered sublingual drops. Starting with a structured, supervised GLP-1 program is the most accessible entry point to GLP-1-based weight management in Pakistan.